Researchers in Gary Lewin’s lab at the Max Delbrück Center have identified an ion channel that contributes to chronic pain, suggesting a new target for pain medication. The study was published in “Brain.”
The Max Delbrück Center, Berlin, celebrates its new, innovative research building with a “topping-out ceremony.” The Imaging Innovation Center, designed by the architectural firm heinlewischer, will host researchers specializing in imaging and…
Berlin-Brandenburg: an international start-up hotspot in the digital health segment
A team led by Prof. Dr. Han Sun from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has elucidated an important mechanism in the function of TREK channels at an atomic level. The results, published in the journal "Nature…
The European Molecular Biology Organization (EMBO) has elected Professor Claudia Langenberg of the Berlin Institute of Health at Charité (BIH), and of the Precision Healthcare University Research Institute (PHURI) at Queen Mary University of London,…
On July 8, the Max Delbrück Center and Bruker will kick off a strategic partnership to build a first-of-its-kind innovation hub for systems medicine. The new center will focus on the development and application of mass spectrometry based single-cell…
A new NMR spectrometer has been in operation at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) since the end of May. What makes it special is that it is based on a new type of ceramic high-temperature superconductor. Peter…
New approach to diminish antibiotic resistance developed by research team from Freie Universität Berlin, the Hebrew University of Jerusalem, and ETH Zurich
Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at Charité – Universitätsmedizin Berlin and the German Center for Neurodegenerative Diseases…
Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery…
